Shares of GW Pharma $GWPH surged on Monday after the drug-maker announced its second successful Phase 3 trial for Epidiolex, intended to cure a rare form of epilepsy. It was the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its candidate Epidiolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.